Adjuvant treatment for gastric cancer: Too much is not enough

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 788-789

  Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXIFLURIDINE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TEGAFUR; URACIL;

ADJUVANT CHEMORADIOTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GASTRECTOMY; HUMAN; JAPAN; LYMPH NODE DISSECTION; NOTE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SOUTH KOREA; STOMACH CANCER; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; STOMACH NEOPLASMS;

EID: 84903541195     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70293-1     Document Type: Note

References (10)

1. Macdonald J, Smalley S, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med 2001, 345:725-730.
2. Cunningham D, Allum W, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
3. Sasako M, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011, 29:4387-4393. SakuramotoS.
4. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet 2012, 379:315-321.
5. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012, 30:268-273.
6. Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014, published online June 19. http://dx.doi.org/10.1016/S1470-2045(14)70025-7.
7. Bajetta E, Floriani I, Bartolomeo M, et al. Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach (ITACA-S) trial: comparison of a sequential treatment with irinotecan plus 5-fluorouracil/folinic acid followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr LBA 4001.
8. Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 2003.
9. Dulak AM, Schumacher SE, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012, 72:4383-4393.
10. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684.